Multifactorial intervention for diabetes control among older users of insulin by Machry, Rafael Vaz et al.
1https://doi.org/10.11606/S1518-8787.2018052000144
Artigo OriginalRev Saude Publica. 2018;52:60
Correspondence: 
Rafael Vaz Machry 
Universidade de Santa Maria 
Centro de Ciências da Saúde 
Prédio 26 A Sala 1337  
Campus Universitário  
Faixa de Camobi km 9 
97105-900 Santa Maria, RS, Brasil 
E-mail: rafael.machry@gmail.com
Received: Apr 17, 2017
Approved: Oct 18, 2017
How to cite: Machry RV, Pedroso 
HU, Vasconcellos LS, Nunes RR, 
Evaldt CA, Yunes Filho EB, et al. 
Multifactorial intervention for 
diabetes control among older users 
of insulin. Rev Saude Publica. 
2018;52:60.
Copyright: This is an open-access 
article distributed under the 
terms of the Creative Commons 
Attribution License, which permits 
unrestricted use, distribution, and 
reproduction in any medium, 
provided that the original author 
and source are credited.
http://www.rsp.fsp.usp.br/
Multifactorial intervention for diabetes 
control among older users of insulin
Rafael Vaz MachryI,II,III, Henrique Umpierre PedrosoI, Luthiele Silva VasconcellosI, Rafaela Ramos 
NunesI, Cibelle de Abreu EvaldtI, Eduardo Bardou Yunes FilhoI,II, Ticiana da Costa RodriguesI,II
I Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Departamento de Medicina Interna. Porto 
Alegre, RS, Brasil
II Universidade Federal do Rio Grande do Sul. Programa de Pós-Graduação em Endocrinologia. Porto Alegre, RS, Brasil
III Universidade Federal de Santa Maria. Centro de Ciências da Saúde. Departamento de Clínica Médica. Santa 
Maria, RS, Brasil
ABSTRACT 
OBJECTIVE: To evaluate if the closer follow-up with the supply of insulin pens and the 
measurement of capillary blood glucose improve the management of older patients with type 2 
diabetes without adequate glycemic control despite extensive therapy.
METHODS: This is a prospective, non-randomized, quasi-experimental study. We have included 
45 patients over 60 years old, from both sexes, with glycated hemoglobin (HbA1c) > 8.5% using 
oral hypoglycemic agents and insulin. The intervention consisted of monthly medical visits, with 
the provision of insulin pens and strips for blood glucose measurement. All patients received 
insulin pen, refills of Neutral Protamine Hagedorn and regular insulin, needles for the pen, blood 
glucose meter, and capillary blood glucose tests (three tests/day). Treatment was adjusted with 
the same endocrinologist monthly for six months. Glycated hemoglobin was measured at baseline 
and 12 and 24 weeks after intervention.
RESULTS: Glycated hemoglobin at baseline was 10.34% (SE = 0.22%) and 8.54% (SE = 0.24%, 
p < 0.001) and 8.09% (SE = 0.21%, p < 0.001) at 12 and 24 weeks after intervention, respectively, 
with a significant reduction from baseline.
CONCLUSIONS: More frequent medical visits, with treatment inputs including the use of 
insulin pens and self-monitoring, have improved glycemic control (reduction of 2.25% in HbA1C, 
on average, at 24 weeks of follow-up). Our data support a change in the management and medical 
behavior of older patients with chronically decompensated diabetes. 
DESCRIPTORS: Aged. Diabetes Mellitus, prevention & control. Glycemic Index, drug effects. 
Hypoglycemic Agents. Insulin, administration & dosage. Blood Glucose Self-Monitoring. 
Clinical Trial. 
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INTRODUCTION
Patients with type 2 diabetes (T2D) may need to use insulin as part of treatment to achieve 
adequate glycemic control. In Brazil, according to the Vigilância de fatores de risco e proteção 
para doenças crônicas por Inquérito Telefônico (VIGITEL) 2015, which is a population-based 
study, the number of patients with diabetes is increasing, and 24.4% of the population over 
65 years of age reported having diabetes in 20141. Nevertheless, the care of these patients 
is hindered by the lack of access to current and new medical monitoring and therapeutic 
technologies. A large study with T2D patients has shown that only 26% of them had good 
glycemic control in the public healthcare system2. 
It is essential to ensure adherence to treatment in order to achieve satisfactory glycemic 
control. Approximately 34.6% of patients with diabetes report that they miss applying 
insulin at least once a month3. The number of days without insulin or with non-adherence 
is higher among patients with obstacles to insulin use (they had more difficulty in applying 
the injection and were not satisfied with the flexibility of insulin injections or presence of 
hypoglycemia)3. On the other hand, using insulin pens to improve adherence is associated 
with reduced healthcare costs4. Patients using pens find it easier to use the insulin and 
fewer report pain on application5.
Pawaskar et al.6 have studied patients using a syringe compared to insulin pens and they have 
observed that syringe users had higher health care costs, although the direct costs of the insulin 
delivery method are higher for pen users. However, the response to the replacement of syringes 
by pens in older patients with chronic decompensated diabetes in clinical trials is not known.
Older patients tend to have higher rates of adherence than younger ones7; however, they 
also need attention, and there are few studies on this population. We have evaluated older 
patients with diabetes treated in the Brazilian public healthcare system who already use high 
doses of insulin and have no adequate glycemic control for long periods. We have developed 
this study including patients aged 60 years or older with chronically uncontrolled diabetes 
who are already monitored at a tertiary hospital. All patients were reassigned to monthly 
medical follow-up with frequent adjustments in treatment, use of insulin pens, and daily 
self-monitoring of blood glucose (SMBG).
METHODS
This is a quasi-experimental study to examine a multiple intervention to improve glycemic 
control, including the replacement of syringes by insulin pens in older patients with T2D 
without adequate glycemic control in a Brazilian tertiary hospital. The Research Ethics 
Committee of the Hospital de Clínicas de Porto Alegre has approved the study protocol. All 
participating patients provided written informed consent. Funding was provided by Conselho 
Nacional de Pesquisa (CNPq) – Brazil and Fundo de Incentivo à Pesquisa (FIPE) of Hospital 
de Clínicas de Porto Alegre.
We invited patients who had been previously scheduled for consecutive medical visits from 
the Diabetes Section – Endocrinology Division of Hospital de Clínicas de Porto Alegre. Patients 
were included between June and December 2014.
We included patients with chronically uncontrolled T2D, 60 years or older, already using 
Neutral Protamine Hagedorn [NPH] insulin, either in association with regular insulin or not, 
with syringes in addition to at least one oral antihyperglycemic agent. We considered patients 
as having chronically inadequate control if glycated hemoglobin (HbA1c) were equal or greater 
than 8.5%, collected less than three months before. There were no limits for higher values of 
HbA1c. We did not include persons who self-declared as unable to self-administer insulin or 
who had a glomerular filtration rate lower than 30 ml/min/1.73 m2 by the MDRD equation.
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All participants received insulin pens, needles for the pens, NPH and regular insulin, as 
well a blood glucose meter and lancets. Patients were instructed on the use of insulin, self-
application, and storage of insulin. Follow-up lasted six months, with monthly visits. At each 
visit, all patients received refills of insulin, needles for the pens, and capillary blood glucose 
strips (three tests/day, at least before breakfast, at lunch, and at dinner, and in the presence 
of symptoms of hypoglycemia), and they returned the used refills in the subsequent visit to 
control non-used units. We removed the remaining amount of refills to calculate the number 
of units of insulin used in the last month. All patients were followed monthly by the same 
endocrinologist at all visits, conducted in the same tertiary hospital.
In the first month, patients continued to use the same prescribed dose of insulin as before 
recruitment. After this, adjustments began to be made based on capillary blood glucose 
annotations according to the protocol or the judgment of the evaluators.
The same endocrinologist (RVM) did adjustments to the therapy in each visit, with the protocol 
created for this study. Patients did not receive information on the self-adjustment of the doses 
of insulin. We considered that fasting capillary glucose was appropriate between 70–130 mg/
dl. To achieve the target, an adjustment treatment was created adjusting basal insulin (NPH) 
or rapid acting insulin (regular). To improve the morning control, the evening dose of the NPH 
insulin was adjusted by increasing or decreasing the previously prescribed dose by 4 IU. To 
adjust the glycemic control before lunch and dinner, the same change was made in the morning 
dose of the NPH insulin by 4 IU. For patients using only bedtime NPH insulin who needed to 
receive another injection in the morning, NPH insulin was introduced at 12 IU before breakfast. 
In case of a high dose of NPH insulin (greater than 40 IU in each application), regular insulin 
was adjusted or introduced (4 IU). The regular dose of insulin was adjusted every 4 IU before 
breakfast, lunch, or dinner (depending on periods without adequate glycemic control).
We asked questions about weekly cases of hypoglycemia and other adverse effects. We 
reviewed the number of medications, antihypertensive drugs, oral antihyperglycemic 
agents, and the number of pills taken daily. We measured blood pressure twice on each 
arm, for the mean value, after relaxing in a sitting position for 10 minutes. We calculated the 
anthropometric measures of weight, height, and body mass index (BMI) (kg/m2).
The questionnaires “Problems Areas in Diabetes – Brazil” (BPAID) and “Diabetes Quality of 
Life” (DQOL) were applied, both validated in Brazil. The questionnaires used do not have a 
standardized cut-off point8,9. The first one evaluates emotional stress related to diabetes in 20 
questions. In the second, we used the variables “impact” and “satisfaction” to evaluate quality 
of life. Other standard variables in this questionnaire are not applicable to the population 
studied. There were 33 questions. These questionnaires were applied in the first and last visit.
Glycated hemoglobin (ion exchange HPLC) was measured at baseline and 12 and 24 weeks 
after recruitment. All analyses were done in the same laboratory (Hospital de Clínicas de 
Porto Alegre). We also looked at the medical records to evaluate the measures of HbA1c 
(same method) at least one year before and six months after the intervention.
The primary endpoint was the reduction of HbA1c in 12 and 24 weeks. Secondary endpoints 
were the reduction of the number of cases of hypoglycemia or the presence of self-reported 
nocturnal (need to awaken the patient at night), asymptomatic (only measurement lower than 
70 mg/dl without symptoms), or severe hypoglycemia (loss of consciousness or otherwise 
need to recover). We considered it hypoglycemia when the measured capillary blood glucose 
was lower than 70 mg/dl or when patients presented symptoms, recovering after eating. We 
also evaluated reduction of blood pressure levels and improving quality of life. The degree of 
compliance was also evaluated. Adherent patients were those who used at least eighty percent 
of the prescribed daily dose in most months, as usually done in clinical studies4,10,11.
To calculate the sample size of 42 patients, we expect an improvement of at least one percent 
after the use of the insulin pen from baseline. We used a power of 90% and alpha error of 
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5%. All analyses were performed on an intention-to-treat basis. We applied the Shapiro-Wilk 
test to evaluate the sample distribution.
Continuous variables with normal distribution were described as mean and standard error 
(SE) and categorical variables were described as number of cases (percentage). We used the 
Student’s t-test to compare groups with continuous variables. To compare all variables using 
the same sample, modified in time, categorical variables were analyzed by McNemar’s test, 
and the analysis of continuous variables for repeated measurements was performed by the 
generalized estimating equation with Bonferroni correction. Analyses were done using the 
SPSS 18.0 software (Chicago, IL).
RESULTS
Forty-five patients were included in the study, 35 of whom completed the follow-up. Six 
patients dropped out because they did not approve the study protocol. One patient had 
acute myocardial infarction requiring myocardial revascularization surgery and subsequent 
prolonged hospitalization for surgical site infection. One patient required hospitalization 
for hip prosthesis infection. One patient suffered lower limb amputation for diabetic foot, 
and another died without a definite cause during psychiatric hospitalization for alcoholism.
The medical records of the patients or the questions asked on the first visit evaluated their 
social and demographic characteristics and the medical conditions at baseline, and they 
are described in Table 1.
Mean HbA1c was 10.34% (SE = 0.22) at baseline (range: 8.7% to 14.6%). At 12 weeks of 
follow-up, HbA1c was 8.54% (SE = 0.24) (p < 0.001). At 24 weeks, HbA1c was 8.09% (SE = 0.21) 
(difference from baseline p < 0.001). There was no difference between the 12 and 24 weeks 
(p = 0.402) (Figure 1). There was a reduction in HbA1c of 2.25% during the intervention period. 
One year before recruitment, HbA1c was 10.08% (SE = 0.32) and 24 weeks before, it was 10.46% 
(SE = 0.32). Curiously, we monitored the value of HbA1c after the conclusion of study. The 
results were 9.77% (SE = 0.34) and 9.46% (SE = 0.46) at 12 and 24 weeks respectively, with no 
difference when compared to baseline values (Figure 1). After completion of the follow-up, 
patients continued to use the insulin pens and perform blood glucose measurements.
Additionally, we compared patients who used sulfonylurea (14 patients) to those who did not use it 
(31 patients). The values of HbA1c at baseline were similar in both cases: 10.3% (SE = 1.38%) versus 
10.4% (SE = 1.59%, p = 0.83). After 24 weeks of follow-up, HbA1c decreased in both groups: -2.42% 
(SE = 1.49%) versus -1.54% (SE = 1.86%, p = 0.43). There was no increased incidence of hypoglycemia 
between the groups. We found no difference among the prescribed dose of NPH insulin, regular 
insulin, or the ratio of regular/NPH insulin between users and non-users of sulfonylurea.
Considering the incidence of hypoglycemia per week, we found a frequency lower than once/
week (mean 0.8 per week [hypoglycemia reported one month before the inclusion]). These 
values did not change during the study (p = 1.00). We detected a decrease in the number of 
patients with asymptomatic hypoglycemia (p = 0.024), but no difference among the number 
of patients with nocturnal (p = 0.07) or severe hypoglycemia (p = 0.25) during follow-up.
During follow-up, there was an increase in the self-reported average number of medications used 
from the fourth month onwards, but not in the number of antihypertensive or antihyperglycemic 
agents, which remained similar during the study. This fact may be explained by other classes 
of drugs (antidepressants, analgesics, or specific treatment for other comorbidities). Systolic 
and diastolic blood pressure levels did not change during the study.
In all patients, there was an increase in the prescribed dose of insulin (IU/kg) and in the ratio 
of regular/NPH insulin from the third month, but the BMI of the patients remained similar 
to the starting one throughout the study (Figure 2).
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Table 1. Characteristics of the older patients with uncontrolled TD2 after intervention. 
Variable Measurement
Age in years (mean and SD) 66.71 (4.11)
Male (%) 28.9
Race (%)
White 62.2
Black 24.4
Other 13.3
Religion (%)
Catholic 73.3
Evangelical 13.3
Spiritualist 4.4
Other 8.8
Family Income (%)a
Up to 1 minimum wage 17.8
1–2 minimum wages 48.9
Over 2 minimum wages 33.3
Years of education (%)
Uneducated or less than 1 year 8.9
1 to 3 years 15.6
4 to 8 years 40.0
9 years or more 35.6
History of smoking (%)
Never smoked 60.0
Current smoker -
Former smoker 40.0
Alcohol consumption (%)
Never drank 60.0
Socially 28.9
Alcohol abusers 02.0
Former drinker 09.1
Diabetic retinopathy (%)b
Absent 11/37 (29.7)
Mild or moderate non-proliferative 11/37 (29.7)
Severe non-proliferative 04/37 (10.8)
Proliferative 11/37 (29.7)
Diabetic nephropathy (%)c
Absent 17/40 (42.5)
Increased albuminuria 15/40 (37.5)
Significantly increased albuminuria 07/40 (17.5)
Nephrotic-range albuminuria 01/40 (02.5)
Diabetic neuropathy (n and %)c
Absent 20/39 (51.3)
Present 19/39 (48.7)
Presence of cerebrovascular disease (n and %)d 02/40 (05.0)
Presence of ischemic cardiomyopathy (n and %)e 13/43 (31.0)
Time of diabetes in years (mean and SD) 15.93 (7.8)
Time using insulin in years (mean and SD) 9.53 (6.03) 
Glycated hemoglobin (mean and SD) 10.34% (0.22)
Positive familiar history for diabetes (%) 64.4
Presence of Hypertension (%) 93.3
Use of sulfonylurea (%) 31.1
Time of hypertension in years (mean and SD) 16.02 (11.09)
Number of medications used (mean and SD) 8.42 (2.32)
Number of antihypertensives (mean and SD) 3.52 (1.08)
Number of pills used (mean and SD) 14.46 (6.42)
Insulin dose per kg/day (mean and SD) 0.85 (0.48)
Regular insulin use (%) 31.1
Body mass index (BMI) (weight/height 2) (mean and SD) 31.70 (4.88)
Systolic blood pressure in mmHg (mean and SD) 138.77 (19.15)
Diastolic blood pressure in mmHg (mean and SD) 70.09 (11.00)
a Minimum wage equal to $220,70 (reference year = August/2015).
b Chart review.
c Chart review; we considered albuminuria > 14 mg/g of creatinine (increased albuminuria) and > 140 mg/g 
of creatinine (significantly increased albuminuria), and neuropathy in patients with a description of positive 
monofilament test, sensorial changes, or suggestive lesions.
d History of transient ischemic attack or stroke.
e History of unstable angina, acute myocardial infarction, or diagnosis of ischemic heart disease.
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Regarding adherence to the prescribed dose of insulin, patients used a mean of 70.07% 
(SE = 3.74) of the prescribed dose of insulin during the first month of study. At subsequent 
visits, all means were greater than 80% (Figure 3).
Additionally, we evaluated the response to early intervention considering as “responders” 
patients who reduced HbA1c at least 0.5% in the first trimester of follow-up. Compared to 
“non-responders”, those patients used more sulfonylureas associated with metformin and 
insulin (p = 0.001) and had higher rates of hypoglycemia until the sixth visit (p = 0.009), with 
no differences in severity and presence of nocturnal or asymptomatic hypoglycemia.
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We compared pre- and post-intervention quality of life. The scores for BPAID were 39.44 
(SE = 3.66) and 34.62 (SE = 4.24, p = 0.107) at baseline and at the end of study, respectively. 
When we stratified by domains, related to emotions, food, treatment, and social life, we also 
found no differences. In the DQOL, we used the variables impact and satisfaction. For the 
variable impact, the scores were 2.27 (SE = 0.11) and 2.43 (SE = 0.12, p = 0.109) at baseline and 
at the end of study, respectively. For the variable satisfaction, the scores were 2.45 (SE = 0.12) 
and 2.57 (SE = 0.13, p = 0.109) at baseline and at the end of study, respectively.
DISCUSSION
In this 24-week study, the multifactorial intervention including the replacement of syringes 
for insulin pens and the implementation of frequent SMBG, with monthly adjustment 
in the treatment, was effective to improve glycemic control among older patients with 
uncontrolled T2D. 
In our study, all patients were treated at a public hospital, were already using high doses of 
insulin, and had chronically uncontrolled T2D despite the efforts of the health care team; 
therefore, another measure was needed to improve glycemic control. Compared to large 
clinical trials with T2D12–14, we found higher levels of HbA1c in the beginning of the study 
(the Veterans Affairs Diabetes Trial (VADT) had approximately 9.4%, the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial had 8.1%, and the Action in Diabetes 
and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation 
(ADVANCE) trial had 7.2% at baseline). In general, these studies also had the possibility of 
introducing other oral medication or starting insulin.
A study performed in basic health care15 with monthly adjustments in the treatment of 
diabetes, including SMBG, did not find any improvement in glycemic control in any patient. 
No improvement in glycemic control was observed even when these authors considered 
only patients with HbA1c greater than 7% at baseline (mean 8.6% [SE = 1.5%]). The initial 
mean HbA1c was lower in this group of patients than in our study and only 21.19% of the 
patients were using insulin. However, many other clinical characteristics were similar 
and, unlike this study, we provided insulin and pen devices and we asked to conduct more 
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Figure 3. Rates of adherence to insulin use, calculated by the mean of the ratio of used units/prescribed 
units and standard error.
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frequent blood glucose tests in our follow-up. Thus, possibly the use of pens may have 
positively influenced the better results found in our study. 
Previous studies have described insulin users as having lower rates of adherence compared 
to users of oral medications for diabetes treatment6,16. Adherence to treatment with insulin 
is usually lower than 75% in patients starting insulin11,16. However, observational studies 
including patients who have used insulin for a longer time have shown similar rates of 
adherence among patients using syringes or pens, both greater than 80%. The long-term 
use of insulin, regardless of pen or syringe, appears to be related to improved adherence6,10. 
Moreover, older patients seem to show better rates of adherence than younger subjects4. 
However, most of these studies are observational and count refills dispensed at the pharmacy, 
according to medical prescription, to measure adherence10,16. In our study, the method to 
evaluate adherence appears to be more precise than in other studies. We counted the amount 
of units of insulin in each refill. Nonetheless, we found higher rates of adherence to treatment 
as described in the literature from the second month of follow-up. 
Another factor that may have justified a significant improvement in glycemic control was the 
possibility of frequent adjustments of insulin. In general, before recruitment, patients were 
seen every 4–6 months, which is a long period between evaluations. During follow-up, we 
adjusted the prescribed dose of insulin every month based on the capillary blood glucose. 
When this intervention was suspended, even after keeping patients on the insulin pen, the 
level of HbA1c returned to values similar to baseline. Although the inclusion criterion was 
the most recent value of HbA1c, all patients had HbA1c similar to this value (more than 
8.5%) at least 24 weeks before recruitment (with chronically poor glycemic control).
The Self-monitoring of Blood Glucose may also have contributed to the improvement of 
glycemic control, but not all results can be justified by this management alone. Results 
presented in previous studies are inconsistent given the variety of methodologies and 
different frequencies of capillary glucose measurements17–20. Our patients underwent three 
measurements daily. A systematic review with meta-analysis has shown a slight decrease 
in favor of SMBG, however with multiples protocols of capillary glucose21. In addition, the 
direct supply of insulin pens, insulin refills, and lancets may have benefited the glycemic 
control. Patients received inputs for the following month. Facilitating access to treatment 
may have influenced outcomes.
Usually, insulin is the third drug included in T2D treatment in the public health system in 
Brazil, with free distribution, after attempting treatment with metformin and sulfonylurea. A 
systematic review and network meta-analysis has assessed the potential decrease of HbA1c 
with various classes of drugs as a third drug. Although the results were similar between oral 
drugs and insulin, the original studies have used much lower doses of insulin than what is 
usually necessary for patients with very poor glycemic control, as in our study. Perhaps the 
effect of insulin has been underestimated22. Current evidence reinforces the maintenance of 
sulfonylurea treatment in patients with T2D when there is secondary failure with this class 
of drugs, with compulsory association with insulin23–25. However, we received some patients 
who were not yet using this drug, and who were using high doses of insulin. In this situation, 
we did not add sulfonylurea in order to not alter the study protocol. Additionally, we did no 
suspend sulfonylurea, only the adjustment of the dose of insulin. We found no difference 
between patients with or without sulfonylurea. However, we believe that, regardless of the 
prescribed dose of insulin, the maintenance of sulfonylurea may help in the glycemic control. 
A possible limitation was the absence of a control group to evaluate the effect of using 
insulin pens (non-randomized study). On the other hand, our objective was to evaluate 
a multifactorial strategy to improve glycemic control in chronically decompensated 
patients treated in the Brazilian Unified Health System. One year before recruitment, with 
conventional medical care, patients did not have satisfactory glycemic control. We also 
realized that patients found it extremely difficult to understand the questionnaires; even 
with poor glycemic control at baseline, they said that they were very satisfied with the 
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result of their treatments, clearly showing the poor understanding of their glycemic control 
and disease. Although several of them said that they preferred to use pens, we could not 
measure this information with validated instruments. One limitation was the small number 
of participants representing a large group of patients with T2D. We also had a high rate 
of drop-outs; despite that, the expressive result in the decrease in HbA1c was statistically 
significant and the intention-to-treat analysis can minimize this limitation.
We found no difference regarding hypoglycemia events. However, the mean HbA1c 
level was higher in the beginning of the study and even lower than baseline; the final 
values were well above the target. Therefore, if more patients had reached the HbA1c 
levels near 7%, we would possibly have more hypoglycemic events per patient. During 
the ACCORD trial13, the group achieved 6.4% of HbA1c on average, compared with 
the group that achieved 7.5% of HbA1c on average; therefore, they had higher rates of 
hypoglycemia and, consequently, needed medical care. In addition, very low levels of 
HbA1c among high-risk patients result in increased mortality, but the rationale for this 
fact remains unexplained26.
In conclusion, strategies to improve the glycemic control in older subjects with T2D work, 
but only during the period of the study with all interventions implemented at the same time. 
The offer of more frequent medical visits and devices to patients can contribute with these 
strategies. The individual effect of each strategy still needs to be further studied.
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